NCT06990269 Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
| NCT ID | NCT06990269 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | ADARx Pharmaceuticals, Inc. |
| Condition | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2030-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 240 participants in total. It began in 2025-11-10 with a primary completion date of 2030-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of GA of the macula secondary to AMD * GA lesions between 2.5 and 12.5 mm2 at screening * Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol * Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol Exclusion Criteria: * Has GA secondary to causes other than AMD * Has active ocular disease that compromises or confounds visual function * History of surgery for retinal detachment * Has ocular condition other than GA secondary to AMD * Use of intravitreal complement inhibitors in study eye * Hereditary or acquired complement deficiency * Active viral, bacterial or fungal infection * Liver injury as evidenced by abnormal liver function tests * Donating blood * History of choroidal neovascularization in the study eye
Contact & Investigator
Aditya Patel, MD
STUDY DIRECTOR
ADARx Pharmaceuticals, Inc.
Frequently Asked Questions
Who can join the NCT06990269 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Geographic Atrophy Secondary to Age-related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06990269 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06990269 currently recruiting?
Yes, NCT06990269 is actively recruiting participants. Contact the research team at info@adarx.com for enrollment information.
Where is the NCT06990269 trial being conducted?
This trial is being conducted at Gilbert, United States, Phoenix, United States, Bakersfield, United States, Beverly Hills, United States and 11 additional locations.
Who is sponsoring the NCT06990269 clinical trial?
NCT06990269 is sponsored by ADARx Pharmaceuticals, Inc.. The principal investigator is Aditya Patel, MD at ADARx Pharmaceuticals, Inc.. The trial plans to enroll 240 participants.